gracecastuc-017_lung_a promising option for people with the most common lung cancer mutation?
Published 11 years ago • 79 plays • Length 5:58Download video MP4
Download video MP3
Similar videos
-
10:10
gracecast-017_lung-cancer_never-smokers with lung cancer
-
5:42
gracecastuc-006 - which patients with advanced lung cancer should potentially receive local therapy?
-
18:51
gracecast-140_lung_highlights in lung cancer, 2012: new options for egfr mutation-positive nsclc
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
6:11
gracecastuc-012_lung_the more you seek, the more you find
-
6:03
gracecastuc-020_lung_case in point: how should we approach someone with a rare egfr mutation?
-
2:25
gracecastuc-075_lung_recommending a repeat biopsy with acqd. resistance to targeted therapy
-
5:27
gracecast-144_lung_highlights in lung cancer, 2013: mek inhibitors for kras mutation-positive nsclc
-
10:43
gracecast-007_lung-cancer_optimal treatment of unresectable locally advanced nsclc
-
5:09
gracecastuc-013_lung_what should we do for a "mixed response" to lung cancer treatment?
-
5:16
gracecastuc 126 lung_is it possible to test for biomarkers on a national scale?
-
5:11
gracecastuc-015_lung_what is the biology of a mixed response in lung cancer?
-
9:49
gracecast-001_lung-cancer_first line chemo for advanced nscl
-
3:43
gracecastuc 120 lung_mutation testing become available beyond the major research centers
-
1:09
gracecastuc-037_lung_repeat biopsy at initial diag. or with acqd. resistance to a targeted therapy?
-
17:36
gracecast-096_lung-cancer_mm in lc pt 1: dr. charles rudin on the lung cancer mutation consortium
-
0:54
gracecastuc-072_lung_how to manage acqd. resistance with single lesion or more diffuse progression?
-
16:39
gracecast-067_lung-cancer_expert round table - nsclc molecular markers case 3
-
8:06
gracecast-145_lung_highlights in lung cancer, 2013: squamous cell nsclc and antipd1